Abstract
We have developed a system for the targeted delivery of adeno–associated virus (AAV) vectors. Targeting is achieved via a bispecific F(ab´)2 antibody that mediates a novel interaction between the AAV vector and a specific cell surface receptor expressed on human megakaryocytes. Targeted AAV vectors were able to transduce megakaryocyte cell lines, DAMI and MO7e, which were nonpermissive for normal AAV infection, 70–fold above background and at levels equivalent to permissive K562 cells. Transduction was shown to occur through the specific interaction of the AAV vector–bispecific F(ab´)2 complex and cell–associated targeting receptor. Importantly, targeting appeared both selective and restrictive as the endogenous tropism of the AAV vector was significantly reduced. Binding and internalization through the alternative receptor did not alter subsequent steps (escape from endosomes, migration to nucleus, or uncoating) required to successfully transduce target cells. These results demonstrate that AAV vectors can be targeted to a specific cell population and that transduction can be achieved by circumventing the normal virus receptor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Samulski, R.J. 1993.Adeno–associated virus: integration at a specific chromosomal locus. Curr. Opin. Genet. Dev. 3:74–80.
Xiao, X., Li, J., and Samulski, R.J. 1996.Efficient long–term gene transfer into muscle tissue of immunocompetent mice by adeno–associated virus vector. J. Virol. 70:8098–8108.
Flotte, T.R., Afione, S.A., and Zeitlin, P.L. 1994.Adeno–associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol. Biol. 11:517–521.
Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O'Malley, K.L. et al. 1994.Long–term expression and phenotypic correction using adeno–associated virus vectors in the mammalian brain. Nat. Genet. 8:148–154.
McCown, T.J., Xiao, X., Li, J., Breese, G.R., and Samulski, R.J. 1996.Differential and persistent expression patterns of CNS gene transfer by an adeno–associated virus (AAV) vector. Brain Res. 713:99–107.
Russell, D.W., Miller, A.D., and Alexander, I.E. 1994.Adeno–associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91:8915–8919.
Flotte, T.R., Afione, S.A., Conrad, C., McGrath, S.A., Solow, R., Oka, H. et al. 1993.Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno–associated virus vector. Proc. Natl. Acad. Sci. USA 90:10613–10617.
Conrad, C.K., Allen, S.S., Afione, S.A., Reynolds, T.C., Beck, S.E., Fee–Maki, M. et al. 1996.Safety of single–dose administration of an adeno–associated virus (AAV)–CFTR vector in the primate lung. Gene Ther. 3:658–668.
Miller, J.L., Donahue, R.E., Sellers, S.E., Samulski, R.J., Young, N.S., and Nienhuis, A.W. 1994.Recombinant adeno–associated virus (rAAV)–mediated expression of a human g–globin gene in human progenitor–derived erythroid cells. Proc. Natl. Acad. Sci. USA 91:10183–10187.
Walsh, C.E., Nienhuis, A.W., Samulski, R.J., Brown, M.G., Miller, J.L., Young, N.S. et al. 1994.Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno–associated virus vector. J. Clin. Invest. 94:1440–1448.
Kessler, P.D., Podsakoff, G.M., Chen, X., McQuiston, S.A., Colosi, P.C., Matelis, L.A. et al. 1996.Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93:14082–14087.
Kumar, S. and Leffak, M. 1991.Conserved chromatin structure in c–myc 5´ flanking DNA after viral transduction. J. Mol. Biol. 222:45–57.
Walsh, C.E., Liu, J.M., Xiao, X., Young, N.S., Nienhuis, A.W., and Samulski, R.J. 1992.Regulated high level expression of a human g–globin gene introduced into erythroid cells by an adeno–associated virus vector. Proc. Natl. Acad. Sci. USA 89:7257–7261.
Chu, T.H., Martinez, I., Sheay, W.C., and Dornburg, R. 1994.Cell targeting with retroviral vector particles containing antibody–envelope fusion proteins. Gene Ther. 1:292–299.
Kasahara, N., Dozy, A.M., and Kan, Y.W. 1994.Tissue–specific targeting of retroviral vectors through ligand–receptor interactions. Science 266:1373–1376.
Russell, S.J., Hawkins, R.E., and Winter, G. 1993.Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21:1081–1085.
Somia, N.V., Zoppe, M., and Verma, I.M. 1995.Generation of targeted retroviral vectors by using single–chain variable fragment: an approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA 92:7570–7574.
Goldman, C.K., Rogers, B.E., Douglas, J.T., Sosnowski, B.A., Ying, W., Siegal, G.P. et al. 1997.Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57:1447–1451.
Wickham, T.J., Carrion, M.E., and Kovesdi, I. 1995.Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor–specific peptide motifs. Gene Ther. 2:750–756.
Wickham, T.J., Segal, D.M., Roelvink, P.W., Carrion, M.E., Lizonova, A., Lee, G.M. et al. 1996.Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70:6831–6838.
Bartlett, J.S., Samulski, R.J., and McCown, T.J. 1998.Selective and rapid uptake of adeno–associated virus type–2 (AAV–2) in brain. Hum. Gene Ther. 9:1181–1186.
Summerford, C. and Samulski, R.J. 1998.Membrane–associated heparan sulfate proteoglycan is a receptor for adeno–associated virus type 2 virions. J. Virol. 72:1438–1445.
Mizukami, H., Young, N.S., and Brown, K.E. 1996.Adeno–associated virus type 2 binds to a 150–kilodalton cell membrane glycoprotein. Virology 217:124–130.
Ponnazhagan, S., Wang, X.–S., Woody, M.J., Luo, F., Kang, L.Y., Nallari, M. et al. 1996.Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno–associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non–permissive for AAV infection. J. Gen. Virol. 77:1111–1122.
Wistuba, A., Weger, S., Kern, A., and Kleinschmidt, J.A. 1995.Intermediates of adeno–associated virus type 2 assembly: Identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69:5311–5319.
Ferrari, F.K., Samulski, T., Shenk, T., and Samulski, R.J. 1996.Second–strand synthesis is a rate–limiting step for efficient transduction by recombinant adeno–associated virus vectors. J. Virol. 70:3227–3234.
Alexander, I.E., Russell, D.W., and Miller, A.D. 1994.DNA–damaging agents greatly increase the transduction of nondividing cells by adeno–associated virus vectors. J. Virol. 68:8282–8287.
Russell, D.W., Miller, A.D., and Alexander, I.E. 1995.DNA synthesis and topoisomerase inhibitors increase transduction by adeno–associated virus vectors. Proc. Natl. Acad. Sci. USA 92:5719–5723.
Montgomery, R.R., Kunicki, T.J., Taves, C., Corcoran, M., and Pidard, D.J. 1983.Diagnosis of Bernard–Soulier syndrome and Glanzmann thrombasthenia with a monoclonal assay of whole blood. J. Clin. Invest. 71:385–389.
Pidard, D., Montgomery, R.R., Bennett, J.S., and Kunicki, T.J. 1983.Interaction of AP–2, a monoclonal antibody specific for human platelet glycoprotein IIb–IIIa complex, with intact platelets. J. Biol. Chem. 258:12582–12586.
Handagama, P., Scarborough, R.M., Shuman, M.A., and Bainton, D.F. 1993.Endocytosis of fibrinogen into megakaryocyte and platelet a–granules is mediated by αIIbβ3 (glycoprotein IIb–IIIa). Blood 82:135–138.
Halbert, C.L., Alexander, I.A., Wolgamot, G.M., and Miller, A.D. 1995.Adeno–associated virus vectors transduce primary cells much less efficiently than immortilized cells. J. Virol. 69:1473–1479.
Ponnazhagan, S., Wang, X.S., Kang, L.Y., Woody, M.J., Nallari, M.L., Munshi, N.C. et al. 1994.Transduction of human hematopoietic cells by the adeno–associated virus 2 vectors is receptor–mediated. Blood 84:742a.
Malik, P., McQuiston, S.A., Yu, X.–J., Pepper, K.A., Krall, W.J., Podsakoff, G.M. et al. 1997.Recombinant adeno–associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line. J. Virol. 71:1776–1783.
Teramoto, S., Bartlett, J.S., McCarty, D., Xiao, X., Samulski, R.J., and Boucher, R.C. 1998.Factors influencing adeno–associated virus–mediated gene transfer to human cystic fibrosis airway epithelial cells: a comparison with adenovirus vectors. J. Virol. 44:8904–8912.
Imai, K., Hareyama, M., Makiguchi, Y., Matsumoto, H., and Hinoda, Y. 1997.Monoclonal antibody–conjugated immunotherapy of cancer. Int. Rev. Immunol. 14:213–227.
Bodey, B., Siegel, S.E., and Kaiser, H.E. 1996.Human cancer detection and immunotherapy with conjugated and non–conjugated monoclonal antibodies. Anticancer Res. 16:661–674.
Jones, N. and Shenk, T. 1979.Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17:683–689.
Goodman, S., Xiao, X., Donahue, R.E., Moulton, A., Miller, J., Walsh, C. et al. 1994.Recombinant adeno–associated virus–mediated gene transfer into hematopoietic progenitor cells. Blood 84:1492–1500.
Samulski, R.J., Srivastava, A., Berns, K.I., and Muzyczka, N. 1983.Rescue of adeno–associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33:135–143.
Samulski, R.J., Chang, L.–S., and Shenk, T. 1987.A recombinant plasmid from which an infectious adeno–associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61:3096–3101.
Bartlett, J.S., Xiao, X., and Samulski, R.J. 1996. Adeno–associated virus vectors for gene transfer, pp. 115–127, in Protocols for gene transfer in neuroscience: towards gene therapy of neurological disorders, Lowenstein, P.R. and Enquist, L.W. (eds.). John Wiley & Sons, Chichester, UK.
Samulski, R.J., Chang, L.–S., and Shenk, T. 1989.Helper–free stocks of recombinant adeno–associated viruses: normal integration does not require viral gene expression. J. Virol. 63:3822–3828.
Sanes, J.R., Rubenstein, J.L.R., and Nicolas, J.F. 1986.Use of a recombinant retrovirus to study post–implantation cell lineage in mouse embryos. EMBO J. 5:3133–3142.
Hirt, B. 1967.Selective extraction of polyoma DNA from infected mouse cells. J. Mol. Biol. 26:365–369.
Acknowledgements
We are grateful to Robert Montgomery of The Blood Center of Southeast Wisconsin for the AP–2 antibody; and are indebted to Rose Wilcher for exceptional technical assistance. This research was aided by NIH grants HL 51818 and HL 42384 to R.C.B., HL 533016 and HL 549638 to R.J.S.; and by CFF grants R026 to R.C.B. and MARZLU96PO to J.S.B.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bartlett, J., Kleinschmidt, J., Boucher, R. et al. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody. Nat Biotechnol 17, 181–186 (1999). https://doi.org/10.1038/6185
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/6185
This article is cited by
-
Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types
Nature Methods (2020)
-
Polarized AAVR expression determines infectivity by AAV gene therapy vectors
Gene Therapy (2019)
-
Gene therapy approaches in the non-human primate model of Parkinson’s disease
Journal of Neural Transmission (2018)
-
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Nature Biotechnology (2016)
-
Enhancing gene delivery of adeno-associated viruses by cell-permeable peptides
Molecular Therapy - Methods & Clinical Development (2014)